Biotech Co.* (Symbol)

Pharma Co. (Symbol/Country)

Change from original agreement

Disclosed Funding ($M)

Terms/Details (Date)

Array BioPharma Inc. (ARRY)


Expansion of their existing drug discovery collaboration to include process research and manufacturing


ICOS has exclusive worldwide rights to develop and market any products resulting from the collaboration; since the collaboration began in 1999, scientists identified an inhibitor of PDE4 (8/00)

Array BioPharma Inc. (ARRY)

Merck & Co. Inc. (NYSE:MRK)

Expansion of existing collaboration


The companies will collaborate to design and synthesize small-molecule libraries exclusively for Merck's drug discovery activities; Array will develop processes for the synthesis of each library in collaboration with Merck scientists and utilize its high-speed synthesis and parallel purification platforms; financial terms were not disclosed (9/00)

Diversa Corp. (DVSA)

Novartis Agribusiness Biotechnology Research Inc. (unit of Novartis AG; Switzerland; NYSE:NVS)

Expanded collaboration to use Diversa's evolution technologies to develop and optimize synthesis routes to crop protection chemicals


Diversa will receive research payments, milestones and product royalties

Genome Therapeutics Corp. (GENE)

Schering-Plough Corp. (NYSE:SGP)

Extension through 9/01 of a 1995 genomics research collaboration to develop anti-infectives for drug-resistant bacteria


Genome Therapeutics has utilitzed its bioinformatics to identify and validate genes and associated proteins as drug discovery targets for Schering; announced in 1995 as a potential $43.5M alliance, excluding royalties, the collaboration has achieved five milestones since its inception, including Genome Therapeutics delivering multiple assays for validated targets and the commencement of high-throughput screening for drug candidates by Schering (7/00)

GLYCODesign Inc. (Canada)*

Seikagaku Corp. (Japan)

Expansion of 11/99 research and development collaboration to identify small-molecule, orally active Core 2 transferase inhibitors displaying anti-inflammatory activity, providing Seikagaku with the options to develop and license one of the compounds for treatment of inflammation

C$25 (US$16.9)

Seikagaku gains additional drug development and licensing options in three additional disease areas: cardiovascular diseases, cancer and diabetes; GLY-CODesign will receive an undisclosed up-front equity investment, milestone and success payments in each new disease area, and royalties on future sales; the value is estimated to be C$25M if Seikagaku exercises all the available options (9/00)

Incyte Genomics Inc. (INCY)

Bio-Active Co. Ltd. (Thailand), BioCat GmbH (Germany), Biomedical Sciences (Korea), B&L Systems (Holland), BS Company for Export & Import (Egypt), Cambridge Bioscience (UK), Genasia Scientifics Inc. (Taiwan), Integrated Sciences Pty Ltd. (Australia), Inmedica (Sweden), Izasa SA (Spain), Jingmei Biotech Co. Ltd. (China), Krabo Industries (Japan), LGC do Brasil (Brazil), M-Medical srl (Italy), Ornat Biochemicals & Laboratory Equipment Ltd. (Israel), Proteigene (France) Research Instruments (Singapore), Shanghai Sinroad Bioengineering Co. (China), and VWR Scientific Products (U.S.)

Incyte's clone reagent sets, or copies of genes and gene-based research tools and services, including LifeSeq Gene-by-Gene


Incyte signed 19 distribution agreements, allowing various companies to market, sell and distribute Incyte's clone reagent sets and gene-based research tools and services; financial terms were not disclosed (8/00)

Lion Bioscience AG (Germany; LEON)

Bayer AG (Germany)

Expansion of existing bioinformatics IT-partner-ship into the field of pharmacophore informatics


Bayer will make a US$25M up-front payment, which includes a licensing fee, research and development funding, and milestone payments between now and March 2003; Lion and Tripos Inc. (TRPS) will retain all rights for the immediate resale of the software systems and solutions developed during the collaboration (10/00)

MediChem Research Inc.*

AstraZeneca (UK; NYSE:AZN)

Renewal of drug discovery collaboration


The 12-month renewal integrates MediChem's medicinal chemistry and parallel synthesis teams to provide the AstraZeneca R&D Charnwood site with high-quality synthetic libraries to advance their drug discovery programs; financial terms were not disclosed (8/00)

Proteome Inc.*

Merck & Co. Inc. (NYSE:MRK)

Expansion of agreement for access to Proteome's BioKnowledge Library of other model organisms


Merck gains access to Proteome's Human Proteome Survey Database of human, mouse and rat proteins, and also access to the G protein-coupled receptor proteome database (9/00)

Xenogen Corp.*

Novartis Research Foundation (unit of Novartis AG; Switzerland; NYSE:NVS)

Licensing agreement/Novartis will gain complete access to Xenogen's suite of technologies for use in preclinical drug development studies at any Novartis site worldwide, including use of Xenogen's real-time in vivo imaging technology


The three-year, multimillion dollar agreement, with an option for an additional four years, is a result of a successful evaluation license of the technology (8/00)


Active Biotech AB (Sweden; ACTIB)

SmithKline Beecham plc (UK; NYSE:SBH)

The two companies agreed to terminate the collaboration for traveler's diarrhea vaccines


Active Biotech has taken back the worldwide rights for the ETEC vaccine project; the ongoing Phase III trials in Mexico and Guatemala are continuing according to plan; all international marketing rights for the SBL cholera vaccine have also been transferred back to Active Biotech; Active will receive a license for Sweden from SB for a second brand of its Havrix vaccine to prevent hepatitis A infections and will be marketed by Active Biotech's Swedish marketing organization, SBL Vaccin (8/00)

Sepracor Inc. (SEPR)

Eli Lilly & Co. (NYSE:LLY)

Terminated licensing and development agreement


Lilly terminated the agreement covering fluoxetine and will return the existing scientific data to Sepracor; fluoxetine, at the highest dose tested, demonstrated a small, but statistically significant increase in QTc prolongation, indicating that development of a lower dose would delay the NDA submission by at least two years; Sepracor has decided not to pursue the fluoxetine program at this time (10/00)


# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange.